首页 | 本学科首页   官方微博 | 高级检索  
检索        


Efficacy of postoperative antiviral combined transcatheter arterial chemoembolization therapy in prevention of hepatitis B-related hepatocellular carcinoma recurrence
Authors:YAN Qiang  NI Jun  ZHANG Guo-lei  YAO Xing  YUAN Wen-bin  ZHOU Lin  ZHENG Shu-sen
Institution:YAN Qiang (Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou,Zhejiang 310003, China;Department of Hepatobiliary and Pancreatic Surgery, Huzhou Central Hospital, Huzhou, Zhejiang 313000, China);NI Jun (Department of Hepatobiliary and Pancreatic Surgery, Huzhou Central Hospital, Huzhou, Zhejiang 313000, China);ZHANG Guo-lei (Department of Hepatobiliary and Pancreatic Surgery, Huzhou Central Hospital, Huzhou, Zhejiang 313000, China);YAO Xing (Department of Hepatobiliary and Pancreatic Surgery, Huzhou Central Hospital, Huzhou, Zhejiang 313000, China);YUAN Wen-bin (Department of Hepatobiliary and Pancreatic Surgery, Huzhou Central Hospital, Huzhou, Zhejiang 313000, China);ZHOU Lin (Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou,Zhejiang 310003, China);ZHENG Shu-sen (Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou,Zhejiang 310003, China);
Abstract:Background Recurrence of hepatitis B-related hepatocellular carcinoma (HCC) after curative resection is the leading factor influencing the prognosis of the disease.Therefore,further improvement of long-term survival may depend on the prevention and treatment of the recurrent tumor.The aim of this research was to investigate the role of antiviral therapy and postoperative transcatheter arterial chemoembolization (TACE) in the prevention and treatment of hepatitis B-related HCC recurrence.Methods One hundred and twenty patients who underwent curative resection of hepatitis B-related HCC between January 2005 and June 2008 at our hospital were enrolled.Patients were divided into four groups according to the post-operative adjuvant therapy they received,i.e.,control,antiviral therapy group,TACE group,and combined group.The disease-free survival (DFS) and the 12-,24-,36-month cumulative recurrence rates were studied.Results There was no significant difference between isolated postoperative antiviral therapy group and control in terms of disease-free survival (P=0.283),while it was significantly higher in the TACE group compared to control (P=0.019).In all patients,however,viral prophylactic therapy combined with/without TACE brought a favorable result compared to those only with/without TACE (P <0.001).Similarly,no matter combined with or without antiviral treatment,postoperative TACE prolonged DFS (P=0.015).Naturally,a combination of viral prophylactic therapy on the baseline TACE significantly benefited patients' postoperative DFS (P=0.047) and vice verse (P=0.002).The 24-month cumulative recurrence rates of combined group were significantly lower than that of isolated control group and antiviral therapy (P <0.001 and P=0.011 respectively).However,36-month recurrence rate was significantly different in the control group compared to the TACE group and combined group (P=0.040 and 0.002 respectively); same as the antiviral group compared to the combined group (P=0.034).Conclusions Post-operative TACE prevents early recurrence while antiviral therapy prevents late recurrence of HCC.Combination of antiviral therapy and TACE are suggested for prevention in HCC patients with high risk of recurrence.
Keywords:hepatocellular carcinoma  antiviral therapy  transcatheter arterial chemoembolization  disease-free survival  recurrence
本文献已被 维普 等数据库收录!
点击此处可从《中华医学杂志(英文版)》浏览原始摘要信息
点击此处可从《中华医学杂志(英文版)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号